Quentin Blackford runs iRhythm, and he explained a $287.5 million purchase with a sentence about scheduling. "We're not going to wait around for an MCT clearance to then figure out whether to introduce one product versus the other," he told MedTech Dive. The clearance he's not waiting on is his own.
iRhythm announced on August 7 that it will buy VitalConnect, the San Jose maker of the VitalPatch biosensor, for $237.5 million in cash and $50 million in stock. The deal should close by the end of the year. MedTech Dive's headline called it growing heart monitoring leadership, which is true, and which is the least interesting thing about the decision.
Look at what iRhythm expects to be selling once it closes. Zio AT, the monitor it sells today, reaches roughly half the mobile cardiac telemetry market. Zio MCT, the next one, is sitting in front of the FDA and aims at another 20 to 30 percent. VitalPatch covers what those two leave behind, in hospitals and in remote monitoring, which is how Blackford gets to a market near $1 billion with about $500 million of it new to iRhythm. Three products, overlapping, sold at once, on purpose.
The gap was in the calendar
It's easy to treat a submission already in review as a launch date. The FDA hands you a range instead, and the range is widening. MedTech Dive ran the numbers in July: 510(k) clearances averaged about 156 days in the first half of 2026, up from about 148 a year earlier, and original PMA approvals stretched to roughly 599 days from about 402. The device center is hiring back after cutting more than 3,000 positions in 2025. None of that is a scandal. It's variance, and variance in a file you have already handed over is variance you can't manage.
So Blackford bought his way out of the sequencing problem. With VitalPatch in the portfolio, nobody at iRhythm has to pick which product leads based on when a letter arrives, or hold a launch while the answer comes back. That's a different purchase than market share, and it's the one worth studying.
Overlap only works if you can name the buyer
Focus is the standard advice, and it's usually right. Carrying three products that do similar things goes wrong when the only thing separating them is a spec sheet. iRhythm's don't split that way. VitalPatch is cleared for hospital and remote monitoring, wears for seven days, and watches for 21 arrhythmias alongside vital signs. Zio is the long-wear ambulatory patch a cardiologist sends home with a patient. Different care setting, and a different person deciding to order it.
I learned that difference from floppy disks. In high school I bought the premium tier every time, the box advertised as 100 percent surface tested, because I had allowance money and no way to check whether a cheaper disk would eat my work. A friend of mine was a product manager at Dysan and claimed credit for the tiering, graded by how much of each production run got scanned for defects. As he told it, the executives scoffed that nobody buys a floppy disk over testing percentages. The top tier outsold everything. Internally the cheap disks almost never failed, but I couldn't see the factory. I could only see the fear the expensive box removed.
Every tier needs a plausible home. That's the test I'd run on iRhythm's three: not whether the products differ, but whether a hospital, a cardiologist and a payer would each land on a different one and feel well served. A customer who buys the smaller option and grows into the bigger one is healthy. A customer who buys the smaller one for exactly the right reasons and gets burned is damage you paid $287.5 million to build.
What I'd steal here is the honesty about the clock. Blackford has a file in review, he refused to let its timing set his product strategy, and he spent cash to take that decision back. Most of us can't write that check, so the move is to stop drawing roadmaps that assume a review lands on schedule, and to start naming which customers go unserved for every month it doesn't.
From Dave’s video library
Dave walks through the commercial questions that have to be answered before a clearance letter turns into a product anyone buys.
I’m here to help you scale.
Work With DavePrefer a smaller first step? Book a $500 one-hour working session →
Dave Saunders is the founder of Base Reality Group and a Fractional CPO for product companies. He was a founder and operator at Galen Robotics, where the surgical-robotics platform earned FDA De Novo authorization in 2023, and he managed a 35-patent portfolio licensed from Johns Hopkins. He wrote Founders Who Finish and publishes The Build. More about Dave →